Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Warfarin
Drug ID BADD_D02373
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indications and Usage **Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
Marketing Status approved
ATC Code B01AA03
DrugBank ID DB00682
KEGG ID D08682
MeSH ID D014859
PubChem ID 54678486
TTD Drug ID D0E3OF
NDC Product Code 76282-328; 43353-054; 65162-764; 70518-2381; 76282-335; 70518-2382; 76282-333; 43353-023; 51407-345; 65162-762; 65162-765; 70518-2383; 71335-1786; 65162-763; 65162-767; 68788-8402; 71610-491; 71610-519; 50090-2646; 50090-5058; 70518-2717; 71610-458; 71610-462; 43353-029; 50090-2936; 51407-346; 65162-769; 43353-030; 65162-768; 70518-2394; 71610-448; 71610-490; 76282-330; 50090-2613; 51407-342; 65162-766; 70518-2816; 76282-329; 76282-331; 76282-334; 50090-3263; 71335-1824; 76282-332; 43353-021; 43353-028; 43353-053; 51407-343; 51407-344; 51407-347; 65162-761; 76282-327; 43353-033; 50090-2645
UNII 5Q7ZVV76EI
Synonyms Warfarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Apo-Warfarin | Aldocumar | Gen-Warfarin | Warfant | Coumadin | Marevan | Warfarin Potassium | Potassium, Warfarin | Warfarin Sodium | Sodium, Warfarin | Coumadine | Tedicumar
Chemical Information
Molecular Formula C19H16O4
CAS Registry Number 81-81-2
SMILES CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lacunar infarction24.04.06.009; 17.08.01.0160.000056%Not Available
Catheter site haemorrhage08.02.02.002; 24.07.01.003; 12.07.02.0020.000056%Not Available
Puncture site haemorrhage08.02.04.007; 24.07.01.034; 12.07.04.0060.000070%Not Available
Hypofibrinogenaemia01.01.01.010--Not Available
Pulmonary calcification22.01.02.0190.000342%Not Available
Dyschezia07.02.03.0050.000028%Not Available
Bladder necrosis24.04.09.006; 20.03.01.0170.000070%Not Available
Facial paresis17.04.03.0020.000028%
Exercise tolerance decreased08.01.03.0360.000042%Not Available
Large intestine polyp07.20.01.010; 16.05.02.0060.000499%Not Available
Calciphylaxis14.04.01.0120.004613%Not Available
Vascular calcification24.03.02.0130.001150%Not Available
Skin induration23.03.03.0200.000042%
Pneumatosis08.01.03.0440.000028%Not Available
Haemodynamic instability24.03.02.0060.000196%Not Available
Oesophageal rupture12.01.17.015; 07.04.05.0050.000070%Not Available
Catheter site erythema23.03.06.014; 12.07.02.003; 08.02.02.0030.000028%Not Available
Large intestinal haemorrhage24.07.02.026; 07.12.03.0030.000137%
Drug tolerance increased08.06.01.004--Not Available
Epigastric discomfort07.01.02.0040.000042%Not Available
Alcohol withdrawal syndrome08.06.02.002; 19.07.06.0050.000028%Not Available
Clonic convulsion17.12.03.0080.000042%Not Available
Tracheal disorder22.04.07.005--Not Available
Allodynia17.02.07.0170.000028%Not Available
Vascular occlusion24.04.02.0150.000028%Not Available
Acquired haemophilia01.01.01.0020.000098%Not Available
Cerebral haematoma24.07.04.006; 17.08.01.0140.000351%Not Available
Haemorrhoidal haemorrhage24.10.02.001; 07.15.03.0020.000230%
Mucosal discolouration08.01.06.0080.000028%Not Available
Vascular insufficiency24.04.02.0140.000028%Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene